CryoCath CE-marks 7F cardiac cryoablation device:
This article was originally published in Clinica
Executive Summary
Canada's CryoCath Technologies has CE-marked for sale in Europe its 7F Freezor catheter cryoablation system for treating cardiac tachyarrhythmias (rapid and irregular heartbeats). As well as being smaller and easier to handle than the company's earlier 9F Freezor product, which was CE-marked last year, the 7F system provides 40% more cooling capacity to treat tachyarrhythmias faster and more effectively, Steve Arless, CryoCath's president and CEO, told Clinica. The new product will be introduced into 20 leading centres this year, with a more widespread commercial launch planned for 2002, says the Kirkland, Quebec firm.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.